These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Criteria for the definition of the eosinophilia-myalgia syndrome. Hertzman PA J Rheumatol Suppl; 1996 Oct; 46():7-12. PubMed ID: 8895176 [TBL] [Abstract][Full Text] [Related]
10. The eosinophilia-myalgia syndrome: what we know, what we think we know, and what we need to know. Clauw DJ; Pincus T J Rheumatol Suppl; 1996 Oct; 46():2-6. PubMed ID: 8895175 [No Abstract] [Full Text] [Related]
11. Once too little, now too much. Weber KT Cardiovasc Res; 1998 Jun; 38(3):541-4. PubMed ID: 9747424 [No Abstract] [Full Text] [Related]
12. [Neuromuscular diseases with eosinophilia]. Pellissier JF; Figarella-Branger D; Serratrice G Med Trop (Mars); 1998; 58(4 Suppl):471-6. PubMed ID: 10410368 [TBL] [Abstract][Full Text] [Related]
13. Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by the eosinophilia-myalgia syndrome. Hertzman PA; Clauw DJ; Duffy J; Medsger TA; Feinstein AR Arch Intern Med; 2001 Oct; 161(19):2301-6. PubMed ID: 11606145 [TBL] [Abstract][Full Text] [Related]
15. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. Smith MJ; Garrett RH Inflamm Res; 2005 Nov; 54(11):435-50. PubMed ID: 16307217 [TBL] [Abstract][Full Text] [Related]
16. Eosinophilia-myalgia syndrome and giant cell myocarditis: a case report and therapeutic approach. Amidon TM; Baldwin JL; George E Heart Dis; 1999; 1(2):66-7. PubMed ID: 11720607 [TBL] [Abstract][Full Text] [Related]
19. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395 [No Abstract] [Full Text] [Related]